Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. develops investigational biologics intended to enhance regulatory T-cell, or Treg, function in neurodegenerative disorders. Company news centers on COYA 302, including clinical and regulatory updates in amyotrophic lateral sclerosis and frontotemporal dementia, biomarker publications, and research on systemic inflammation, lipid peroxidation, axonal injury, and Treg dysfunction.
Coya updates also cover its Treg-focused therapeutic platforms, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Recurring business developments include collaboration activity with Dr. Reddy’s Laboratories, milestone-related revenue disclosures, operating results, stockholder communications, and board or governance changes.
Coya Therapeutics (NASDAQ: COYA) announced that founder Howard Berman, Ph.D., has stepped down as Executive Chairman and from the Board, and that Mark H. Pavao has been appointed as an independent director. The move follows a CEO transition begun in November 2024 that established Arun Swaminathan, Ph.D., as CEO. The company highlighted Pavao’s >30 years of commercial experience and said COYA 302 is approaching an important Phase 2B ALSTARS data readout as the company advances toward potential commercialization.
ReAlta Life Sciences (NASDAQ:AVIR) appointed Howard Berman, Ph.D. as Chairman and CEO and Kia Motesharei, Ph.D. as President and COO on March 24, 2026.
The hires add capital markets, deal-making, and late-stage clinical development experience as ReAlta advances pegtarazimod into late-stage trials for HIE and other indications.
Coya Therapeutics (NASDAQ: COYA) highlighted a peer‑reviewed study showing peripheral immune dysregulation in frontotemporal dementia (FTD). Blood from 27 FTD patients and 25 controls showed significantly reduced Treg suppressive function (p<0.05) and elevated pro‑inflammatory mediators including TNFα and multiple chemokines (p<0.05–0.01).
Previously reported investigator data of low‑dose IL‑2 plus CTLA‑4 Ig showed increased Treg number/function within two weeks, no cognitive decline over 22 weeks, and favorable tolerability.
Coya Therapeutics (NASDAQ: COYA) reported FY2025 results and a corporate update highlighting clinical and financial progress. Key milestones include IND acceptance for COYA 302 in FTD, ALSTARS Phase 2 launch with ~25 U.S./Canada sites, a U.S. patent for an RTU IL-2 formulation, and cash of $46.8M with financing extending runway into 2H 2027.
FY2025 revenue included $7.9M collaboration revenue and $6.7M license revenue; net loss was $21.2M.
Coya Therapeutics (NASDAQ: COYA) will host a live webinar on February 17, 2026 at 3:00 p.m. ET / 12:00 p.m. PT titled “Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress.”
The event will review ALS biology, recent treatment advances, and patient needs, highlight Coya’s immunotherapy combination COYA 302, and provide an overview of the ALSTARS Phase 2 clinical trial design and enrollment. Fred Grossman, D.O., FAPA, will moderate with experts Stanley Appel, M.D., and James Berry, M.D., MPH. Pre-registration is open, attendees may submit written Q&A, and a recording will be posted to the company website.
Coya Therapeutics (Nasdaq: COYA) entered a definitive securities purchase agreement to sell 2,522,727 shares of common stock at $4.40 per share in a private placement for gross proceeds of approximately $11.1 million, expected to close on or about January 30, 2026.
Investors are Dr. Reddy’s Laboratories ($10.0 million) and Greenlight Capital ($1.1 million). Proceeds will fund tech transfer and scale-up manufacturing for low-dose IL-2 to support commercial readiness of COYA 302. The company will file a resale registration statement with the SEC within 45 days of closing.
Coya Therapeutics (NASDAQ: COYA) issued a letter outlining 2026 priorities focused on advancing COYA 302 in ALS and FTD and progressing COYA 303 in Alzheimer’s disease. The company has initiated the ALSTARS Phase 2 ALS trial with active dosing and U.S. and Canadian sites, and targets full enrollment in H2 2026 with a topline readout in Q1 2027. Coya reported $46.8 million cash as of December 31, 2025, no debt, non-dilutive funding of $8.4 million from Dr. Reddy’s, and a cash runway into H2 2027. Additional translational datasets and a Phase 2a FTD study initiation are planned in 2026.
Coya Therapeutics (NASDAQ: COYA) reported results from a 9-patient, investigator-initiated open-label study of low-dose IL-2 plus CTLA4-Ig in frontotemporal dementia over 22 weeks of dosing. The study observed statistically significant increases in regulatory T-cell (Treg) numbers and suppressive function beginning at two weeks and sustained through week 22. Cognitive measures remained stable: MoCA (baseline 13.5, week 22 14) and CDR-FTLD (baseline 4.8, week 22 5.5) showed no meaningful decline. Safety was tolerable with no serious adverse events and injection-site erythema in 33.3% of participants. Company commented on advancing COYA 302 to a controlled Phase 2 trial.
Coya Therapeutics (NASDAQ: COYA) announced that the U.S. FDA has accepted its IND for COYA 302 to treat frontotemporal dementia (FTD) on January 5, 2026. FTD affects about 60,000 Americans, has an average onset age of 58 and average survival of 7.5 years. The company positions COYA 302 to enhance regulatory T cell (Treg) anti-inflammatory function as a disease‑modifying approach for sporadic FTD. Coya also expects to announce topline results soon from an investigator‑initiated open‑label study evaluating low‑dose IL‑2 and CTLA4‑Ig in mild‑to‑moderate FTD.
Coya Therapeutics (NASDAQ: COYA) announced that Health Canada accepted the Clinical Trial Application for COYA 302 on December 23, 2025, allowing activation of Canadian clinical sites for the ALSTARS phase 2 placebo‑controlled trial in amyotrophic lateral sclerosis (ALS).
The CTA acceptance permits patient enrollment at Canadian ALS centers, expanding recruitment alongside ongoing U.S. sites and enabling broader site activation and patient access for the study.